Apr 23, 2026 8:30am EDT RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Apr 14, 2026 8:30am EDT Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Apr 08, 2026 8:30am EDT RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Apr 01, 2026 2:20pm EDT RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Mar 30, 2026 4:05pm EDT RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
Mar 26, 2026 8:30am EDT RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
Mar 23, 2026 8:30am EDT RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Mar 20, 2026 8:30am EDT RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
Feb 27, 2026 8:30am EST RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
